Orexigen Therapeutics Inc fka OREX

[BluSkies]

This seems low. Breakout soon?

[schnitz]

OREX news out!!!

[Jimmy Quick]

Conference call tomorrow after close. Big potential for producing a high return turnaround here. Steady hold last two trading days.

[FairviewInvestor]

Perhaps, but I don't regret getting out at 3.80! when the Technical Indicators were saying.. bagholding time if you stay in.

Just pulled up the Chart and ran through technicals. sure an optimistic bounce off 2.20
maybe that is saying.. 2.20 is bottom. who knows.

so far it hasn't crossed any meaningful moving average to indicate a bullish reversal with this little, tiny bounce to 2.35

OK. so it crossed the 10sma.. but the 10sma isn't a recognized bullish sign for a reason.

good luck. I'll still watch for now.

I'll try and keep an eye for when a bullish trend actually forms. other than that, guessing the bottom is a fools game. jmo

[Jimmy Quick]

Big volume day (more than 2.5 times avg daily volume) with an end of day push. November 3rd conference call with business update.

[Jimmy Quick]

Wow some investor just grabbed over 20,000 shares. Conference call on Nov 3 should explain whats around the corner here, and we can determine how undervalued this stock really is.

[Jimmy Quick]

Question yourself, why does management go to stock options at this point. Because they know the return potential for such stock options is better than cash they can pay management. Secondly, management isn't turning to options if they feel like they are going to fail here. Two big deals in the works for sale of diet drug and they don't even have to do the fieldwork for it, Canadien and a European company's will be doing it for them. Just manufacture and dispense so to speak.

[Jimmy Quick]

The diet drug is going to hit the European markets this quarter and the Canadien markets the first or second quarter of 2017. This stock is about to rebound.

[Shenzebengal]

Still a DuD...Always a DuD.

[Shenzebengal]

And your point is??????

[Ludo2705]

What the hell it decreases every day!! I hope it Will change on August 4th

[Shenzebengal]

It would seem after the reverse 1 for 10 share split this stock OREX appears to be heading for troubled times once again.

[FairviewInvestor]

Trading at $3.59 today.. what's going to keep it from falling, falling, falling?

Only thing will some sort or PR or Pump.

so toxic at the moment.

someone tell me different, I'm all ears

[FairviewInvestor]

Check SEC filings.. they issued stock options to pretty much everyone in higher management.

This company is all about selling stock IMO. any website for a supposedly really good company who touts Stock prices, Investor relations, as a major part of their Message..

IMO is a RED Flag.

I dumped this toxic stock on the 3.80 drop.

Chart is UGLY

[Ludo2705]

What does that mean endless option?

[FairviewInvestor]

Next Catalyst? Seems to be holding some ground here.. even in light of the endless SEC docs on Options that came out last week

[jones99]

Orexigen Therapeutics (OREX +0.50%) rallied over 4% in after-hours trading after its top shareholder, Baupost, said it may convert/exercise notes/warrants of up to 4.7 million common shares.

[elbiatcho1]

Just a 1-10 split.

And not even talking about bowling.

[Moto260]

Nothing goin on in here huh

[©PROPHETABLE]

Buy bye

[Ludo2705]

When a company posts earnings, the reports are intensely examined by investors and analysts alike. Earnings are important because they can give insight into the profitability of a company. Covering Street analysts are looking for Orexigen Therapeutics, Inc. (NASDAQ:OREX) to report quarterly EPS of $-0.15. The company is next expected to publish earnings on or around 2016-08-04 for the period ending 2016-06-30. In the same quarter last year, the company posted EPS of $-0.18. The company most recently posted quarterly earnings per share of $-0.15. Leading up to the earnings report, the Zacks Research consensus using polled analysts was $-0.1. The gap in the numbers was $-0.05 which created a surprise factor of -50%. Surprise factors are important to view as a company releases earnings. Surprise factors may create significant stock price movements after the release.

Covering analysts often adjust projections before and after the earnings period. Presently, analysts polled by Zacks Research have a mean target price of $1.025 on shares. This target is including 4 different analysts taken into consideration by Zacks Research. Analyst standpoints may vary on where they anticipate the stock heading in the future. Out of all the polled analysts, the most bullish estimate has the stock hitting 2 in the next year. The analyst with the low end target price views shares going to $0.5 within the same period. Zacks Research compiles analyst ratings using a scale that spans from 1 to 5. If the company has a ratings score of 1, this would indicate a Strong Buy. If the company has a 5 rating, this would signify a Strong Sell. Combining all the ratings on Orexigen Therapeutics, Inc. (NASDAQ:OREX), the present mean is sitting at 3.2.

[Sone]

Yeah it's so exciting watching this ho back down to .4

[Ludo2705]

This is strange there are no more followers here

[Ludo2705]

Orexigen Therapeutics (NASDAQ:OREX) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. The business earned $5 million during the quarter, compared to analyst estimates of $7.78 million. Orexigen Therapeutics’s revenue for the quarter was up 16.3% compared to the same quarter last year. Analysts anticipate that Orexigen Therapeutics, Inc. will post ($0.50) EPS for the current fiscal year.
OREX has been the subject of several recent analyst reports. Zacks Investment Research reaffirmed a “buy” rating and set a $2.25 price objective on shares of Orexigen Therapeutics in a research report on Sunday, January 31st. Leerink Swann cut shares of Orexigen Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $4.50 to $2.00 in a research report on Tuesday, February 23rd. RBC Capital cut shares of Orexigen Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $5.00 to $1.00 in a research report on Monday, February 29th. JPMorgan Chase & Co. cut shares of Orexigen Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, February 29th. Finally, Piper Jaffray decreased their price objective on shares of Orexigen Therapeutics from $11.00 to $5.00 and set an “overweight” rating for the company in a research report on Monday, February 29th. One analyst has rated the stock with a sell rating and nine have given a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $2.61.
Orexigen Therapeutics, Inc (NASDAQ:OREX) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company’s product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

[Ludo2705]

Sure..

[Ludo2705]

"We believe that by successfully executing on our plans, Orexigen can achieve profitability beginning in full year 2019 and that the capital we raised in March in connection with the Contrave acquisition will be sufficient to get us there," Narachi said.

[Ludo2705]

How could it be it has so decreased these last months?

[swiftearl]

Im holding

[Sone]

Back to .40

[bfsingle]

people wont hold over the weekend. looking like a sell off day

[TheWhaler]

No diluting that I know of

[Ludo2705]

What is the OS? Are they still diluting right now?

[guchu]

Stocks Intraday Alert: Orexigen Therapeutics, Inc. (NASDAQ:OREX), Tyson Foods, Inc. (NYSE:TSN)

http://stockznews.com/stocks-intraday-alert-orexigen-therapeutics-inc-nasdaqorex-tyson-foods-inc-nysetsn/

[xyz1002]

Trend is upward and no dilution. So hold your breath.

[TheWhaler]

I'm going to hold tight and see how the day plays out, anything could happen.

[Sone]

Thoughts for tomorrow ?

[guchu]

Orexigen Therapeutics, Inc. (NASDAQ:OREX) & Medtronic PLC (NYSE:MDT) Healthcare Stocks Alert

On Wednesday, Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) gained 51.56% to $0.640. The share price is trading in a range of $0.45 – $0.65. The stock exchanged hands with 13.78 Million shares contrast to its average daily volume of 1.97 Million shares.

Orexigen Therapeutics, Inc. (OREX) declared that the United States District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen and Takeda Pharmaceuticals against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell a generic version of the presently approved dose of Contrave® (naltrexone HCl / bupropion HCl extended release) tablets preceding to the expiration of U.S. Patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. There are 10 Contrave patents listed in the Orange Book, the last of which expires in 2032.

Orexigen and Takeda filed the lawsuit on the basis that Actavis’ projected generic product infringes the Contrave patents. In a Markman ruling, also known as a claim construction ruling, the Court determines the meaning of disputed patent claim terms at issue in patent litigation. The Markman hearing for the Actavis litigation was held on May 24, 2016. In a June 6, 2016 Markman ruling, Judge Richard G. Andrews adopted Orexigen’s projected constructions for the majority of the disputed claim terms


http://wallstrt24.com/orexigen-therapeutics-inc-nasdaqorex-medtronic-plc-nysemdt-healthcare-stocks-alert/2413432/

[TheWhaler]

22million share short

shortsqueeze.com/shortinterest/stock/OREX.htm

[xyz1002]

Big move cometh. short term traders and profit takers out.

[guchu]

Orexigen Stock Gains More than 50% on Markman Hearing

main points:

1) shares shot up 51.6% on a favorable Markman hearing in the company’s patent infringement lawsuit against Actavis

2)Orexigen is currently working on growing sales of the product. Following the acquisition of U.S. rights, the company is looking to adopt a targeted approach in growing Contrave sales. Orexigen will focus on differentiating Contrave from generic amphetamines and will work on improving the gross to net ratio through managed care and pharmacy discount strategies. Contrave should benefit from a more targeted sales effort. The company is planning a third quarter relaunch and expects Contrave to achieve market share of 10% - 11% by 2018. Orexigen is hiring 160 sales reps to promote the product.

https://www.zacks.com/stock/news/219826/orexigen-stock-gains-more-than-50-on-markman-hearing?cid=CS-MKTWTCH-HL-219826

[naturalborninvestor]

Will close over $0.60. Pretty sure.

[TheWhaler]

Holding strong at this price, looks ready to rip EOD or tomorrow! If it holds shorts will want to get out before the weekend IMO.

[guchu]

OREX
5 Stocks Under $10 Set to Soar

https://www.thestreet.com/story/13602467/1/5-stocks-under-10-set-to-soar.html?puc=TSMKTWATCH&cm_ven=TSMKTWATCH

[guchu]

Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Most Popular Healthcare Penny Stocks Among Hedge Funds

http://www.insidermonkey.com/blog/most-popular-healthcare-penny-stocks-among-hedge-funds-458697/

[dangerousrhythm]

yesterday was the pump todays the dump

[TheWhaler]

No worries, lots of profit takers this morning. I see some good buys coming in.

[Sone]

Comon bounce!

[TheWhaler]

Shorts trying to cover

[TheWhaler]

$289K dollars pre-market, don't miss out!

[TheWhaler]

Just bought in premarket @ .59